Articles · Symptoms

Hair Loss During Perimenopause

Why estrogen decline drives follicle shrinkage, and which treatments have real evidence.

5 min read · Published May 30, 2026 · Updated August 28, 2026

Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.

Hair Loss During Perimenopause

Hair loss affects up to 52% of postmenopausal women, making it one of the most common physical changes of the transition.[1] Despite that, it rarely gets discussed alongside hot flashes or broken sleep. Many women notice gradual diffuse thinning, a wider parting, or more shedding at the brush without connecting it to the same hormonal shift driving their other symptoms.

Understanding the mechanism makes clear why this type of hair loss looks and behaves differently from the sudden shedding that follows illness or stress, and why treatment needs a different approach.

The Hormonal Mechanism

Hair follicles are estrogen-sensitive tissue. Throughout reproductive life, estrogen lengthens the growth (anagen) phase of the hair cycle and supports the thickness and color of each hair shaft.[2] When estrogen declines at menopause, that support is withdrawn.

The pattern that results is driven by the relative rise in androgen activity. As estrogen falls, testosterone and its more potent form dihydrotestosterone (DHT, converted by the enzyme 5-alpha-reductase) are no longer counterbalanced. DHT binds androgen receptors in scalp follicles and triggers follicle shrinkage: the gradual conversion of thick terminal hairs into fine, short vellus hairs.[2] This is the same process that drives male pattern hair loss, but in women it tends to produce diffuse thinning across the crown and a widening parting rather than a receding hairline or complete baldness.

Oxidative stress and low-grade inflammation, both of which increase after estrogen withdrawal, compound the process by impairing scalp blood flow and nutrient delivery to follicles.[1] The combined result is slower growth, finer individual hairs, less density, and sometimes a change in texture.

Rule Out Thyroid and Iron First

Thyroid disorders and iron deficiency are both common in perimenopausal women, and both cause hair loss that is clinically indistinguishable from pattern hair loss. Before assuming the cause is hormonal, a blood test covering TSH, ferritin, and a full blood count is warranted.

Iron deficiency is easy to miss during perimenopause: heavier, more irregular periods increase blood loss, yet the symptom gets blamed on menopause rather than prompting a look at iron stores. Ferritin below 30 to 50 mcg/L can contribute to hair loss even when hemoglobin is normal. Correcting iron deficiency often produces noticeable improvement within several months.

Hypothyroidism, even subclinical, disrupts the hair cycle and causes diffuse thinning. Its symptoms (fatigue, weight changes, cold intolerance, brain fog) overlap heavily with perimenopausal symptoms, making it easy to miss without testing.

What Helps

Minoxidil (topical). Minoxidil is the best-evidenced topical treatment for female pattern hair loss. It works by lengthening the growth phase and stimulating follicle activity. The 2% and 5% topical solutions are both licensed for women; the 5% concentration produces greater hair count improvements in trials, though scalp irritation is more common. Minoxidil requires sustained use: improvements emerge over 3 to 6 months and reverse on stopping.[3] It does not address the androgen mechanism and works best as maintenance once existing hair has been preserved.

HRT. For women who have other reasons to consider systemic HRT, restoring estrogen can slow the androgen-driven process by re-establishing the androgen-estrogen balance. A pilot study in Japanese postmenopausal women found that estradiol replacement produced measurable improvements in hair shaft diameter and growth rate.[4] The evidence for HRT specifically for hair outcomes is small in scale, but the mechanism is sound, and women on HRT frequently report hair improvement as a secondary benefit.

Spironolactone (off-label). Spironolactone is an aldosterone blocker that also blocks androgen receptors and inhibits 5-alpha-reductase, reducing DHT’s effect on scalp follicles. It is used off-label for female pattern hair loss at doses of 50 to 200 mg/day and has reasonable evidence from observational studies and small trials. Contraindicated in pregnancy; requires blood pressure and electrolyte monitoring.

Broader anti-androgen options, including flutamide and finasteride off-label in postmenopausal women, have evidence in small trials. These should be discussed with a dermatologist.

When to See a Doctor or Dermatologist

Hair loss warrants medical assessment if:

A doctor can arrange the initial blood screen and refer to dermatology if needed. Dermatologists can perform scalp dermoscopy and biopsy to tell pattern hair loss (diffuse, manageable) from scarring alopecias (patchy, inflammatory, needing urgent treatment to prevent permanent loss).

Treatments Without Reliable Evidence

Despite widespread marketing, evidence for biotin supplementation in women without biotin deficiency is negligible. Most women with adequate diets are not biotin-deficient, and taking extra biotin does not stimulate hair growth. High-dose biotin can also interfere with thyroid and other blood test results, which is a practical problem when you are investigating hair loss.

Supplement formulations marketed for hair growth (typically combining biotin, collagen peptides, and various vitamins) lack trial evidence in menopausal women. Some individual ingredients have plausible mechanistic support (adequate zinc, iron, and protein are needed for normal hair growth), but the products themselves have not been tested against the clinical question.


References

[1] Panza, G., et al. (2025). Menopause and hair loss in women: Exploring the hormonal transition. Journal of Cosmetic Dermatology. https://pubmed.ncbi.nlm.nih.gov/40318238/

[2] Marks, D. H., Mirmirani, P. (2024). Menopause, skin and common dermatoses. Part 1: hair disorders. Clinical and Experimental Dermatology. https://pmc.ncbi.nlm.nih.gov/articles/PMC10092469/

[3] Olsen, E. A., Dunlap, F. E., Funicella, T., et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology, 47(3), 377-385. https://doi.org/10.1067/mjd.2002.124088

[4] Nakamura, M., et al. (2024). Clinical and phototrichogrammatic evaluation of estradiol replacement therapy on hair growth in postmenopausal Japanese women with female pattern hair loss. Journal of Cosmetic Dermatology, 22(12). https://pmc.ncbi.nlm.nih.gov/articles/PMC10615536/

Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.